Zentalis Pharmaceuticals announces the granting of temptation under the Nasdaq list of Qaeda 5635 (C) (4) – Zentalis Pharma (NASDAQ: Zntl)

San Diego, March 03, 2025 (Globe Neuwais) – Zintalis^® Pharmaceuticals, Inc. ZntlIt is a vital pharmaceutical company in the clinical stage that develops the first and best -class inhibitors in its class for patients with ovarian cancer and other types of tumor, today it announced that on March 3, 2025, the Compensation Committee on the Board of Directors of Zentalis has given options that are not eligible to buy 5,000 shares of common shares for the employee who was employed in the new stock. Stock options and stock units are granted under the incentive incentive prize plan in Zentalis Pharmaceuticals, 2022 (Enas 2022 plan) as materials urging this individual in employment with ZENTALIS according to the Nasdaq 5635 list (C) (4).

The seduction plan for 2022 is used exclusively to grant stock prizes to individuals who were not previously employed in Zentalis, or after an impossible work period of non -employment, as materials urging each person who is involved in employment with Zentalis, according to the Nasdaq 5635 list (C) (4).

The price of stock options is $ 1.92 per share, which equals the price of closing the shared shares of Zentalis in the Nasdaq Global market in the date of the grant. Stock options range for 10 years and will settle over a period of four years, with 25 % of options on the first anniversary of the date of the start of the evaluation and the remaining 75 % of the options that fall in equal monthly installments over the three years after that. The restricted shares units will end over a period of four years, with 25 % of the stock units restricted to both the first, second, third and fourth anniversary of the date of the start of the work.

The fueling of stock options and stock units restricted to the employee’s continuous service to Zentalis is subject to every date to give up.

About Zentalis Pharmaceuticals
Zentalis^® Pharmaceuticals, Inc. It is a biomedical pharmaceutical company for clinical stage. Azenosertib is evaluated as a monolithic treatment and combines multiple tumor types in clinical trials and has widespread potential. In clinical trials, Azenosertib was well tolerated and an anti -tumor activity as one agent across multiple tumors. The company also takes advantage of its extensive experience and capabilities to translate its science to enhance research in additional fields of opportunities for Azovirt outside Brock. Zentalis has operations in San Diego.

For more information, please visit www.zentalis.com. Follow Zentalis on X/Twitter on @Zentalisp And on LinkedIn in www.linkedin.com/company/zentalis-pharmaceuticals.

Communication authorities:
Hibo Wang – Chief Business Office
Ron Molfar – Investors Relations
Ir@zentalis.com